Novartis AG - 15 Year Stock Price History | NVS
Historical daily share price chart and data for Novartis AG since 2011 adjusted for splits and dividends. The latest closing stock price for Novartis AG as of June 15, 2026 is 151.56.
- The all-time high Novartis AG stock closing price was 163.64 on February 27, 2026.
- The Novartis AG 52-week high stock price is 170.46, which is 12.5% above the current share price.
- The Novartis AG 52-week low stock price is 112.34, which is 25.9% below the current share price.
- The average Novartis AG stock price for the last 52 weeks is 137.48.
| Novartis AG Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 149.6161 | 134.4480 | 163.6390 | 133.8370 | 151.5600 | 13.28% |
| 2025 | 114.0986 | 90.8893 | 135.0880 | 90.8893 | 133.7980 | 46.95% |
| 2024 | 98.3692 | 91.0575 | 113.1110 | 86.6134 | 91.0484 | 0.02% |
| 2023 | 86.2837 | 79.6704 | 94.7810 | 71.9634 | 91.0305 | 16.14% |
| 2022 | 73.1996 | 72.8697 | 81.0009 | 64.4638 | 78.3830 | 8.06% |
| 2021 | 72.4330 | 75.2409 | 78.8987 | 66.0944 | 72.5380 | -3.65% |
| 2020 | 69.2393 | 73.0524 | 76.1760 | 56.3450 | 75.2887 | 3.34% |
| 2019 | 65.9963 | 56.1350 | 73.3755 | 56.1350 | 72.8523 | 27.13% |
| 2018 | 54.9404 | 54.5517 | 61.1234 | 48.3752 | 57.3036 | 5.95% |
| 2017 | 51.6065 | 45.2697 | 55.8209 | 43.5293 | 54.0879 | 19.46% |
| 2016 | 47.4293 | 51.3017 | 51.9082 | 42.0126 | 45.2759 | -12.04% |
| 2015 | 57.9576 | 53.6722 | 63.4884 | 50.2308 | 51.4752 | -4.52% |
| 2014 | 51.0000 | 44.3072 | 56.2321 | 44.0146 | 53.9107 | 19.16% |
| 2013 | 40.9254 | 34.6110 | 45.2472 | 34.5406 | 45.2416 | 31.81% |
| 2012 | 30.9898 | 30.1980 | 34.6815 | 27.9144 | 34.3237 | 15.67% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $293.951B | $54.532B |
| Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |